

Neurodevelopment not impacted by glucocorticoids in preemies

January 11 2018



(HealthDay)—Use of inhaled glucocorticoids in extremely preterm

infants for the prevention of bronchopulmonary dysplasia does not lead to a higher rate of neurodevelopmental disability at 2 years, according to a study published in the Jan. 11 issue of the *New England Journal of Medicine*.

Dirk Bassler, M.D., from University of Zurich, and colleagues randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to receive early (within 24 hours after birth) inhaled budesonide or placebo. A long-term composite outcome of neurodevelopmental disability among survivors included [cerebral palsy](#), cognitive delay (a Mental Development Index score of

Citation: Neurodevelopment not impacted by glucocorticoids in preemies (2018, January 11) retrieved 3 May 2024 from

<https://medicalxpress.com/news/2018-01-neurodevelopment-impacted-glucocorticoids-preemies.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--